



(12) Translation of
European patent specification

(11) NO/EP 2630962 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 38/02 (2006.01)
A61K 31/19 (2006.01)
A61K 31/785 (2006.01)
A61K 38/16 (2006.01)
A61P 25/28 (2006.01)

Norwegian Industrial Property Office

(21) Translation Published 2018.11.12

(80) Date of The European Patent Office Publication of the Granted Patent 2018.06.27

(86) European Application Nr. 13166080.5

(86) European Filing Date 2010.08.19

(87) The European Application's Publication Date 2013.08.28

(30) Priority 2009.08.20, US, 274687 P
2010.02.11, US, 337612 P

(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
Designated Extension States: BA; ME; RS

(62) Divided application EP2405749, filing date 2010.08.19

(73) Proprietor YEDA RESEARCH & DEVELOPMENT COMPANY, LTD., P.O. Box 95, 76100 Rehovot, Israel

(72) Inventor Klingler, Ety, 16 Agadati Street, 39930 Tel Aviv, Israel

(74) Agent or Attorney ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54) Title **Low Frequency Glatiramer Acetate Therapy**

(56) References
Cited: KHAN O ET AL: "Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every - other - day injections in relapsing -remitting multiple", MULT.SCLER. (14, SUPPL. 1, S296, 2008) 0 REF. ISSN: 1352-4585 AV - WAYNE STATE UNIV, SCH MED, DETROIT, MI, USA., P902, 2008, XP009161078,, ANONYMOUS: "Teva Provides Update on FORTE Trial", INTERNET CITATION, 7 July 2008 (2008-07-07), XP002743817, Retrieved from the Internet: URL:<http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1554743> [retrieved on 2015-08-31], FLECHTER SHLOMO ET AL: "Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration.", CLINICAL NEUROPHARMACOLOGY 2002 JAN-FEB

LNKD- PUBMED:11852290, vol. 25, no. 1, January 2002 (2002-01), pages 11-15, XP009161076, ISSN: 0362-5664, SIMPSON DENE ET AL: "Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis.", CNS DRUGS, vol. 16, no. 12, 2002, pages 825-850, XP009161077, ISSN: 1172-7047, YONG WEE V ET AL: "Immunological Responses to Different Doses of Glatiramer Acetate in MS: Analyses from the FORTE Trial", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 72, no. 11, Suppl. 3, 1 March 2009 (2009-03-01), page A39, XP002743818, ISSN: 0028-3878, COHEN J A ET AL: "Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.", NEUROLOGY 20 MAR 2007 LNKD- PUBMED:17372130, vol. 68, no. 12, 20 March 2007 (2007-03-20), pages 939-944, XP002679784, ISSN: 1526-632X, US-A1- 2007 161 566, CAON CHRISTINA ET AL: "Randomized, Prospective, Rater-Blinded, Four Year Pilot Study To Compare the Effect of Daily Versus Every Other Day Glatiramer Acetate 20 mg Subcutaneous Injections in RRMS", NEUROLOGY, vol. 72, no. 11, Suppl. 3, March 2009 (2009-03), page A317, XP009161100, & 61ST ANNUAL MEETING OF AMERICAN-ACADEMY-OF-NEUROLOGY; SEATTLE, WA, USA; APRIL 28 -29, 2009 ISSN: 0028-3878, FLECHTER S ET AL: "Comparison of glatiramer acetate (Copaxone(R)) and interferon beta-1b (Betaferon(R)) in multiple sclerosis patients: An open-label 2-year follow-up", JOURNAL OF THE NEUROLOGICAL SCIENCES, vol. 197, no. 1-2, 15 May 2002 (2002-05-15), pages 51-55, XP002679780, ISSN: 0022-510X

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 5 **1.** Glatirameracetat i form av en farmasøytisk sammensetning for anvendelse i behandling av en menneskelig pasient som lider av en relapserende form av multippel sklerose i et regime med tre subkutane injiseringer av en 40 mg dose av glatirameracetat hver uke med minst én dag mellom hver subkutane injisering, og hvori den farmasøytiske sammensetningen ytterligere omfatter mannitol og har en pH i området 5,5 til 7,0.
- 10 **2.** Glatirameracetat i form av en farmasøytisk sammensetning for anvendelse ifølge krav 1, som reduserer hjerneatrofi.
- 15 **3.** Glatirameracetat i form av en farmasøytisk sammensetning for anvendelse ifølge hvilket som helst av kravene 1 eller 2, hvori den menneskelige pasienten ikke har mottatt glatirameracetatterapi før initiering av behandlingen.